Status:

NOT_YET_RECRUITING

Efficacy of Fuzheng Tongfu Jiedu Prescription for Treating Gastrointestinal Dysfunction Associated With Sepsis

Lead Sponsor:

Dongzhimen Hospital, Beijing

Collaborating Sponsors:

Beijing University of Chinese Medicine

Conditions:

Sepsis Abdominal

Gastrointestinal Dysfunction

Eligibility:

All Genders

50-90 years

Phase:

PHASE1

PHASE2

Brief Summary

This study is a single-center, randomized, double-blind, placebo-controlled trial.

Detailed Description

The study is designed to evaluate efficacy and safety of FZTFJD for treating gastrointestinal dysfunction associated with sepsis compared to placebo in combination with conventional western medicine t...

Eligibility Criteria

Inclusion

  • Clinical diagnosis of sepsis-induced gastrointestinal dysfunction with Acute AGI grade I-III.
  • 50-90 years old, regardless of gender.
  • Sequential Organ Failure Assessment (SOFA) score ≥ 2.
  • Diagnosed with sepsis-induced gastrointestinal dysfunction within 24 hours.
  • Voluntary participation with signed informed consent.

Exclusion

  • ICU length of stay ≤ 3 days (due to death, discharge, or transfer), rendering gastrointestinal function evaluation unfeasible.
  • Patients with allergies or allergic constitution to the investigational herbal medications.
  • Inability to measure intra-abdominal pressure or abdominal circumference due to obesity (weight \> 150 kg), trauma, or surgical factors.
  • Severe organic diseases: lower gastrointestinal bleeding, malignancies, cirrhosis, chronic renal failure (uremic stage), hematologic disorders, HIV, etc.
  • History of gastrointestinal surgery.
  • Long-term use of corticosteroids or immunosuppressants.
  • Severe psychiatric disorders or inability to cooperate with trial protocols.
  • Participation in other clinical trials within 30 days.
  • Pregnant or lactating women.
  • Participated in other clinical studies in the past 3 months.

Key Trial Info

Start Date :

April 25 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 30 2026

Estimated Enrollment :

70 Patients enrolled

Trial Details

Trial ID

NCT06933238

Start Date

April 25 2025

End Date

June 30 2026

Last Update

April 18 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Ethics Committee of Dongzhimen Hospital

Beijing, Beijing Municipality, China, 100700